Detalles de la búsqueda
1.
The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States.
J Med Econ
; 25(1): 650-659, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35502563
2.
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
J Mark Access Health Policy
; 9(1): 1889841, 2021 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33708361
3.
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
J Mark Access Health Policy
; 7(1): 1601484, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31105909
Resultados
1 -
3
de 3
1
Próxima >
>>